Vital KSK Holdings, Inc. (TYO:3151)
1,283.00
-8.00 (-0.62%)
Dec 5, 2025, 3:30 PM JST
Vital KSK Holdings Revenue
Vital KSK Holdings had revenue of 152.06B JPY in the quarter ending September 30, 2025, with 0.82% growth. This brings the company's revenue in the last twelve months to 603.53B, up 2.23% year-over-year. In the fiscal year ending March 31, 2025, Vital KSK Holdings had annual revenue of 600.37B with 2.19% growth.
Revenue (ttm)
603.53B
Revenue Growth
+2.23%
P/S Ratio
0.10
Revenue / Employee
160.68M
Employees
3,756
Market Cap
62.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 600.37B | 12.89B | 2.19% |
| Mar 31, 2024 | 587.48B | 7.71B | 1.33% |
| Mar 31, 2023 | 579.77B | 2.52B | 0.44% |
| Mar 31, 2022 | 577.25B | 40.22B | 7.49% |
| Mar 31, 2021 | 537.03B | -25.48B | -4.53% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 4.42T |
| Otsuka Holdings | 2.42T |
| Astellas Pharma | 2.01T |
| Daiichi Sankyo Company | 1.98T |
| Chugai Pharmaceutical | 1.21T |
| Terumo | 1.06T |
| Olympus | 977.65B |
| HOYA Corporation | 892.50B |